Olanzapine Prevents the PCP-induced Reduction in the Neurite Outgrowth of Prefrontal Cortical Neurons via NRG1

Scientific Reports
Qingsheng ZhangXu-Feng Huang

Abstract

Accumulating evidence suggests that reducing neurite outgrowth and synaptic plasticity plays a critical role in the pathology of cognitive deficits in schizophrenia. The N-methyl-D-aspartate receptor antagonist phencyclidine (PCP) can induce symptoms of schizophrenia as well as reduce dendritic spine density and neurite growth. The antipsychotic drug olanzapine may improve these deficits. This study aimed to investigate: (1) if olanzapine prevents PCP-induced suppression of neurite outgrowth and synaptic protein expression; (2) if olanzapine affects the Akt-GSK3 signaling pathway; and (3) the role of neuregulin 1 (NRG1) in this process. Immunofluorescence revealed that PCP treatment for 24 hours reduces both neurite length (28.5%) and the number of neurite branches (35.6%) in primary prefrontal cortical neuron cultures. PCP reduced protein and mRNA expressions of synaptophysin (24.9% and 23.2%, respectively) and PSD95 (31.5% and 21.4%, respectively), and the protein expression of p-Akt (26.7%) and p-GSK3β (35.2%). Olanzapine co-treatment prevented these PCP-induced effects in normal neurons but not in neurons from NRG1-knockout mice. These results indicate that NRG1 mediates the preventive effects of olanzapine on the PCP-induc...Continue Reading

References

Jan 5, 2000·The American Journal of Psychiatry·I C WrightE T Bullmore
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Apr 26, 2002·Neuroreport·Peter KalusWerner Zuschratter
Apr 2, 2004·The American Journal of Psychiatry·James E BlackWilliam T Greenough
Jan 22, 2005·Current Opinion in Pharmacology·Brian J MorrisJudith A Pratt
Jun 15, 2006·Cellular and Molecular Neurobiology·Joseph T Coyle
Dec 23, 2006·NeuroImage·Alexandra BadeaWilliam C Wetsel
Apr 27, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Maria BjarnadottirThorkell Andresson
Jun 6, 2007·Archives of General Psychiatry·Richard S E KeefeUNKNOWN Neurocognitive Working Group
Jul 20, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Gang LeiKenneth M Johnson
Oct 4, 2007·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Carmen Villmann, Cord-Michael Becker
May 15, 2008·Nature Reviews. Neuroscience·Lin Mei, Wen-Cheng Xiong
Nov 8, 2008·Journal of Visualized Experiments : JoVE·Lutz G W Hilgenberg, Martin A Smith
Jun 17, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·John D ElsworthRobert H Roth
Aug 14, 2012·Journal of Cellular Biochemistry·Zitao ZhangGuoyong Yin
Jan 29, 2014·The International Journal of Neuropsychopharmacology·Qingsheng ZhangXu-Feng Huang
Feb 20, 2014·Progress in Neuro-psychopharmacology & Biological Psychiatry·Qingsheng ZhangXu-Feng Huang
Jul 24, 2014·Cell Communication and Signaling : CCS·Chirayu D Pandya, Anilkumar Pillai

❮ Previous
Next ❯

Citations

Jun 25, 2017·Neuroscience and Biobehavioral Reviews·Angela IannitelliGiuseppe Bersani
May 23, 2018·Medicinal Research Reviews·Xu-Feng Huang, Xueqin Song

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

geNorm
Quantity One
SPSS

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here